SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-240257"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-240257" > Tumour volume reduc...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004320naa a2200517 4500
001oai:DiVA.org:uu-240257
003SwePub
008150106s2015 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2402572 URI
0247 a https://doi.org/10.1002/pbc.252072 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Dantonello, Tobias Mu Paediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germany4 aut
2451 0a Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma
264 c 2014-09-27
264 1b Wiley,c 2015
338 a print2 rdacarrier
520 a BACKGROUND: Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes.PROCEDURE: Patients with IRSG-III RME <21 years and non-response (NR, <33% volume reduction) in five consecutive CWS-trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub-classified as Objective Response (OR, <0%-33% reduction) or Stable/Progressive Disease (SPD).RESULTS: Fifty-nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk-factors including age, tumour size, and TN-classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk-factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN-classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n = 20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001).CONCLUSION: Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
7001 a Stark, Monikau Paediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germany4 aut
7001 a Timmermann, Beate4 aut
7001 a Fuchs, Jörg4 aut
7001 a Selle, Barbara4 aut
7001 a Linderkamp, Christin4 aut
7001 a Handgretinger, Rupert4 aut
7001 a Hagen, Rudolf4 aut
7001 a Feuchtgruber, Simone4 aut
7001 a Kube, Stefanie4 aut
7001 a Kosztyla, Daniel4 aut
7001 a Kazanowska, Bernarda4 aut
7001 a Ladenstein, Ruth4 aut
7001 a Niggli, Felix4 aut
7001 a Ljungman, Gustaf,d 1958-u Uppsala universitet,Pediatrik,Barnonkologisk forskning/Ljungman4 aut0 (Swepub:uu)gustaflm
7001 a Bielack, Stefan S4 aut
7001 a Klingebiel, Thomas4 aut
7001 a Koscielniak, Ewau Paediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germany4 aut
7102 a Paediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germanyb Pediatrik4 org
7730 t Pediatric Blood & Cancerd : Wileyg 62:1, s. 16-23q 62:1<16-23x 1545-5009x 1545-5017
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-240257
8564 8u https://doi.org/10.1002/pbc.25207

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy